galeratx.com - GRTX Income before deduction of interest, taxes and amortization

Brandmark of Galera Therapeutics Inc. (GRTX)

Is it worth investing in Galera Therapeutics (GRTX), whose radiation-induced stomatitis treatments rely on grants and investments? The EBITDA financial metric provides the answer, and the value of captures this indicator. Risks are increasing due to the complete outsourcing of testing and drug production to third-party contractors. Meanwhile, Galera Therapeutics is implementing software robots for data analysis and automating laboratory molecule screening.

GRTX: Galera Profit before payment of interest, taxes and amortization 07/04/2022 - 11/15/2026

Galera Therapeutics, Inc. - analytical breakdowns and key metrics (GRTX)

- market value and analyst target forecast:
Market Price galeratx.com|GRTX - Consensus Target
- issuer market value details:
Market Value Galera Therapeutics Inc.|GRTX - Total Company Value
- book capitalization information:
Share Book Value Galera Therapeutics|GRTX - Company Book Value|Market Value to Book Value Ratio galeratx.com|GRTX - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Capital Galera Therapeutics|GRTX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Galera|GRTX - Company Aggregate Debts|Debts to Book Capitalization Ratio Galera Therapeutics Inc.|GRTX - Company Long-Term Debt|Short-Term Debt Galera Therapeutics|Intermediate Coverage Ratio galeratx.com
- earnings and valuation multiples information:
GRTX - Company Net Income|Future Profit Galera Therapeutics|GRTX - Price to Earnings Ratio|Market Cap to Projected Earnings Galera|GRTX - PEG Multiple|Enterprise Value to EBITDA Multiple Galera Therapeutics, Inc.|GRTX - Operating profit EBITDA|Net earnings per share (EPS TTM) Galera Therapeutics|GRTX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months galeratx.com|GRTX - Earnings growth in current year|Expected net earnings per share growth next year Galera Therapeutics
- sales and revenue data:
GRTX - Company Revenue|Company Future Revenue Galera|GRTX - P/S Multiple|Forward P/S Multiple Galera|GRTX - Revenue Growth YoY (Last 12 Months)
Summary company analytics:Galera Therapeutics, Inc., GRTX
Original product of galeratx.com

To stress-test long-term positions, it is critical for an investor to evaluate the actual cash flow from core operations before taxes and depreciation. Analyzing the level of net operating income before depreciation allows Galera Therapeutics (GRTX) to confirm the monetization of its radiation tissue protection drugs, transforming steady hospital demand into actual liquidity, which determines the fundamental stability of the business.

Competitors of Galera Therapeutics (GRTX)

Geron (GERN) - Profit before interest, taxes and amortization|NBTX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BCYC (Bicycle Therapeutics PLC)|CytomX Therapeutics, Inc. (CTMX) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization CATX (Perspective Therapeutics Inc)|Profit before payment of interest, taxes and amortization Genelux Corporation|Profit before payment of interest, taxes and amortization MOLN|Operating profit EBITDA ONCY|Operating profit EBITDA Lisata (LSTA)|Moleculin Biotech - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization MTEM (Molecular Templates Corp)